AstraZeneca PLC’s new antibacterial, Zavicefta (ceftazidime plus avibactam), has been recommended for approval in the EU by the top advisory panel, the Committee for Medicinal Products for Human Use (CHMP), for use in the treatment of patients infected with multi-drug resistant bacteria, so-called “superbugs”, as well as several other severe bacterial infections.
The committee recommended approval for infections caused by multi-drug resistant pathogens on the basis of a limited set of data,...






